Navigation Links
Mylan Files Annual Report on Form 10-K for Year Ended Dec. 31, 2009
Date:3/2/2010

PITTSBURGH, March 2 /PRNewswire-FirstCall/ -- Mylan Inc. (Nasdaq: MYL) today announced that its Annual Report on Form 10-K, containing audited consolidated financial statements for the year ended Dec. 31, 2009, as filed with the U.S. Securities and Exchange Commission on Feb. 26, 2010, is available through its Web site (www.mylan.com). In addition, the company's shareholders may receive a hard copy of the Annual Report, free of charge, upon request to Investor Relations at 724-514-1813.

This press release is being issued pursuant to NASDAQ Listing Rule 5250(d)(1)(C).

Mylan Inc. ranks among the leading generic and specialty pharmaceutical companies in the world and provides products to customers in more than 140 countries and territories. The company maintains one of the industry's broadest and highest quality product portfolios supported by a robust product pipeline; operates one of the world's largest active pharmaceutical ingredient manufacturers; and runs a specialty business focused on respiratory, allergy and psychiatric therapies. For more information, please visit www.mylan.com.

SOURCE Mylan Inc.

Back to top

RELATED LINKS
http://www.mylan.com

'/>"/>

SOURCE Mylan Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine news :

1. Mylans Matrix Receives Tentative FDA Approval Under PEPFAR for Efavirenz, Lamivudine and Tenofovir Disoproxil Fumarate Tablets
2. Mylan Parts Ways with Chief Financial Officer Jolene Varney
3. Mylan Launches First Generic Version of Xopenex(R) Inhalation Solution (Concentrate), 0.25%
4. Mylan Begins Marketing First Generic Version of BenzaClin(R) Acne Treatment
5. Mylans Matrix Receives First and Only Tentative FDA Approval Under PEPFAR for Generic Version of Atripla(R) HIV Treatment
6. Mylan Pharmaceuticals Receives Final FDA Report and Reaffirms Its 48-Year Exemplary Record of Quality
7. President Clinton and Mylan Chairman and CEO Robert J. Coury Announce New Agreement to Lower Price of Treatment for Patients with Drug-Resistant HIV in Developing Countries
8. Mylan Chairman and CEO Robert J. Coury to Ring NASDAQ Stock Market Closing Bell
9. Mylan Announces Enhancements to Executive Management Team
10. Mylan Reports That the FDA Determined That All Accusations Were Unfounded
11. Mylan Reiterates and Stands Behind Its 48-Year Commitment and Track Record of Quality
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/25/2017)... Marietta, GA (PRWEB) , ... April 25, 2017 ... ... implant and instrument solutions, announces the continuation of its strategic partnership with and ... surgeons in developing nations in the safe and effective management of complex spine ...
(Date:4/24/2017)... ORLANDO, FLORIDA (PRWEB) , ... April 24, 2017 ... ... of telehealth technology yesterday, featuring Bring Your Own Device (BYOD) capabilities at Telehealth ... compliment LG CNS’ pre-packaged telehealth bundles, which pairs medical devices with a pre-programmed ...
(Date:4/24/2017)... ... , ... The Santana Telehealth Project was honored with the 2017 ATA Humanitarian ... Association’s annual conference, on April 23 in Orlando, FL. , “I am proud that ... of the poor and underserved in other parts of the world,” said Jonathan Linkous, ...
(Date:4/24/2017)... ... ... As part of the nationwide Days of Remembrance effort led by the ... Nazi persecution, Center for Medicine after the Holocaust (CMATH) announced that it ... Germany and Poland next week. , The Fourth Biennial CMATH Champions Trip to Germany ...
(Date:4/24/2017)... ... 24, 2017 , ... The bar for just about everything—apparel, eyewear, cars and ... air of pop and film stardom.(1) Not to be left out is that most ... now run the gamut from being encrusted with jewels and precious metals to, at ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... , April 20, 2017  RXi Pharmaceuticals ... innovative therapeutics that address significant unmet medical needs, ... from the Company,s consumer product development program, based ... the Society for Investigative Dermatology (SID) 76 th ... advance and promote the sciences relevant to skin ...
(Date:4/20/2017)... April 20, 2017   ZappRx, Inc ., a digital ... prescribing process, today announced it closed $25 million in Series ... capital firm based in Seattle that ... Partners . The Series B round included participation from ... 2014, and GV (formerly Google Ventures). As part ...
(Date:4/20/2017)... 2017 Eyevensys, a private biotechnology ... gene expression technology that enables the safe, local, sustained ... a wide range of ophthalmic diseases, announces it has ... Regulatory Agency (MHRA) to advance its technology into clinical ... The ...
Breaking Medicine Technology: